Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMDX-2011P as a retinal tracer in CAA
NCT05709314Phase 2Recruiting
- Sponsor
- Amydis
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Device-based Delivery, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AMDX-2011P in cerebral amyloid angiopathy (CAA), sponsored by Amydis. Primary endpoint: Adverse Events Profile at 8 days. Started Jul 2024; status: recruiting.
02
Drugs
AMDX-2011P
03
Conditions
cerebral amyloid angiopathy (CAA)
Beyond the preview
Go deeper on NCT05709314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05709314.